Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone(CHOP) is an eicient treatment of non-Hodgkin’s lymphoma(NHL). This study aimed to assess the eicacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab(R-CHOP) by examining the stem cell mobilization in NHL patients. Factors afecting the collection of CD34+ cells were also explored.Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were inancially eligible received R-CHOP for autologous peripheral blood stem cell(APBSC) mobilization; the remaining 25 patients received CHOP.Results: The median CD34+ cell yield was 7.01 × 106 cells/kg body weight(range 1.49–28.39 × 106 cells/kg body weight), with only two patients failing to meet the target CD34+ cell harvest of ber of apheresis procedures per patient was 1(range 1–3). The≥2.0 APBS× 106 cells/kg body weight. The median numC mobilization yield of the CHOP group appeared to be higher than that of the R-CHOP group(P response(CR) rate in = 0.005), whereas the success rate was similar between groups. R-CHOP elevated the completeB cell lymphoma patients as compared with CHOP(P = 0.01). No signiicant diferences in toxicity or engraftment were observed between the two groups.Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy efectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma. Background: The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is an eicient treatment of non-Hodgkin’s lymphoma (NHL). This study aimed to assess the eicacy and toxicity of dose-adjusted CHOP alone or in combination with rituximab R-CHOP) by examining the stem cell mobilization in NHL patients. Factors afecting the collection of CD34 + cells were also explored. Methods: Our retrospective study included 39 patients eligible for autologous stem cell transplantation: 14 patients who expressed CD20 and were financially qualified received The remaining 25 patients received CHOP. Results: The median CD34 + cell yield was 7.01 × 10 6 cells / kg body weight (range 1.49-28.39 × 10 6 cells / kg body weight) , with only two patients failing to meet the target CD34 + cell harvest of ber of apheresis procedures per patient was 1 (range 1-3). The> 2.0 APBS × 106 cells / kg body weight. The median numC mobilizat The yield of the CHOP group was to be higher than that of the R-CHOP group (P response (CR) rate in = 0.005), while the success rate was similar to groups. R-CHOP elevated the complete B cell lymphoma patients as compared with CHOP (P = 0.01). No signiicant diferences in toxicity or engraftment were observed between the two groups. Conclusion: The present study demonstrated that dose-adjusted CHOP chemotherapy efectively mobilized APBSCs in NHL patients and that the addition of rituximab to dose-adjusted CHOP chemotherapy elevated the CR rate for patients with B-cell lymphoma.